Alumis Inc (ALMS) - Total Assets
Based on the latest financial reports, Alumis Inc (ALMS) holds total assets worth $411.94 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Alumis Inc (ALMS) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Alumis Inc - Total Assets Trend (2022–2025)
This chart illustrates how Alumis Inc's total assets have evolved over time, based on quarterly financial data. See ALMS book value for net asset value and shareholders' equity analysis.
Alumis Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Alumis Inc's total assets of $411.94 Million consist of 77.3% current assets and 22.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.8% |
| Accounts Receivable | $2.08 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $50.96 Million | 12.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Alumis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Alumis Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alumis Inc's current assets represent 77.3% of total assets in 2025, a decrease from 94.8% in 2022.
- Cash Position: Cash and equivalents constituted 21.8% of total assets in 2025, down from 23.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 12.4% of total assets.
Alumis Inc Competitors by Total Assets
Key competitors of Alumis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Alumis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.34 | 6.01 | 2.56 |
| Quick Ratio | 4.34 | 6.01 | 2.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $244.91 Million | $255.28 Million | $32.49 Million |
Alumis Inc - Advanced Valuation Insights
This section examines the relationship between Alumis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.66 |
| Latest Market Cap to Assets Ratio | 7.31 |
| Asset Growth Rate (YoY) | 20.8% |
| Total Assets | $411.94 Million |
| Market Capitalization | $3.01 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Alumis Inc's assets at a significant premium (7.31x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Alumis Inc's assets grew by 20.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alumis Inc (2022–2025)
The table below shows the annual total assets of Alumis Inc from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $411.94 Million | +20.81% |
| 2024-12-31 | $340.99 Million | +280.52% |
| 2023-12-31 | $89.61 Million | -17.15% |
| 2022-12-31 | $108.17 Million | -- |
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment o… Read more